Literature DB >> 1680024

Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.

J E Gervasoni1, S Z Fields, S Krishna, M A Baker, M Rosado, K Thuraisamy, A A Hindenburg, R N Taub.   

Abstract

Four well defined multidrug-resistant cell lines and their drug-sensitive counterparts were examined for intracellular distribution of daunorubicin (DNR) by laser-assisted confocal fluorescence microscopy: P-glycoprotein-negative HL-60/AR cells, and P-glycoprotein-positive P388/ADR, KBV-1, and MCF-7/ADR cells. Both drug sensitive cell lines (HL-60/S, P388/S, KB3-1, and MCF-7/S) and drug-resistant cell lines (HL-60/AR, P388/ADR, KBV-1, and MCF-7/ADR) exposed to DNR showed a similar rapid distribution of drug from the plasma membrane to the perinuclear region within the first 2 min. From 2-10 min, the drug sensitive HL-60/S, P388/S, and MCF-7/S cells redistributed drug to the nucleus and to the cytoplasm in a diffuse pattern. In contrast, drug-resistant HL-60/AR, P388/ADR, and MCF-7/ADR redistributed DNR from the perinuclear region into vesicles distinct from nuclear structures, thereby assuming a "punctate" pattern. This latter redistribution could be inhibited by glucose deprivation (indicating energy dependence), or by lowering the temperature of the medium below 18 degrees C. The differences in distribution between sensitive and resistant cells did not appear to be a function of intracellular DNR content, nor the result of drug cytotoxicity. Drug-sensitive KB3-1 and -resistant KBV-1 cells did not fully follow this pattern in that they demonstrated an intracellular DNR distribution intermediate between HL-60/S and HL-60/AR cells with both "punctate" and nuclear/cytoplasmic uptake sometimes in the same cell. These data indicate that the intracellular distribution of DNR is an important determinant of drug resistance regardless of the overexpression of P-glycoprotein. The intracellular movement of drug requires the presence of glucose and a temperature above 18 degrees C, implicating energy-dependent processes and vesicle fusion in the distribution process. This intracellular transport of DNR away from the nucleus in multidrug-resistant cells may protect putative cell targets such as DNA against drug toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680024

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.

Authors:  Marlon S Mathews; Van Vo; En-Chung Shih; Genesis Zamora; Chung-Ho Sun; Steen J Madsen; Henry Hirschberg
Journal:  J Environ Pathol Toxicol Oncol       Date:  2012       Impact factor: 3.567

3.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.

Authors:  M A Izquierdo; G L Scheffer; M J Flens; G Giaccone; H J Broxterman; C J Meijer; P van der Valk; R J Scheper
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 6.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies.

Authors:  A J Cooper; M C Hayes; P M Duffy; C L Davies; C J Smart
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

8.  Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

Authors:  Wei Feng; Mavurapu Satyanarayana; Yuan-Chin Tsai; Angela A Liu; Leroy F Liu; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2009-02-20       Impact factor: 6.514

9.  Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents.

Authors:  Wei Feng; Mavurapu Satyanarayana; Liang Cheng; Angela Liu; Yuan-Chin Tsai; Leroy F Liu; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2008-09-05       Impact factor: 3.641

Review 10.  Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.

Authors:  Enrico P Spugnini; Gennaro Citro; Stefano Fais
Journal:  J Exp Clin Cancer Res       Date:  2010-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.